



356 7 78
Views CrossRef citations to date Altmetric


Perspectives

Convergence of decision rules for value-based pricing of new innovative drugs

Afschin Gandjour

Pages 209-213 | Published online: 18 Oct 2014

Cite this article <https://doi.org/10.1586/14737167.2015.972374>



Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Full Article

Figures & data

References

Citations

Metrics

Reprints & Permissions

Read this article

Abstract

Given the
introduc
internati
maximiz
policies
sequenc
any g
inter
best for
effective
internati
acceptal

Keywords

We Care About Your Privacy

We and our 907 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting "I Accept" enables tracking technologies to support the purposes shown under "we and our partners process data to provide," whereas selecting "Reject All" or withdrawing your consent will disable them. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the ["privacy preferences"] link on the bottom of the webpage [or the floating icon on the bottom-left of the webpage, if applicable]. Your choices will have effect within our Website. For more details, refer to our Privacy Policy. [Here](#)

We and our partners process data to provide:

...

I Accept

Reject All

Show Purpose



Acknowledgements

The author would like to thank three anonymous reviewers for very helpful comments on an earlier draft.

Financial & competing interests disclosure

The author has no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.

No writing assistance was utilized in the production of this manuscript.

Key issues

- Genes have been found in the brain of patients with VBP (Ventricular Brain Pathology).
- The brain is the primary site of action for the drug.
- The drug is a potent inhibitor of the enzyme.
- The drug is a potent inhibitor of the enzyme.
- The drug is a potent inhibitor of the enzyme.



×

es have (VBP)

imally


der a l as the

st.

erbid question.

- In the long term, it is best for VBP countries in Europe to implicitly collude and set cost-effectiveness thresholds at the level of the lowest acceptable VBP country.
- In response, manufacturers might support initiatives for differential pricing according to national income and ability to pay.

Notes

 Share

Related research

People also read

Recommended articles

Cited by
7



Information for

- Authors
- R&D professionals
- Editors
- Librarians
- Societies

Opportunities

- Reprints and e-prints
- Advertising solutions
- Accelerated publication
- Corporate access solutions

Open access

- Overview
- Open journals
- Open Select
- Dove Medical Press
- F1000Research

Help and information

- Help and contact
- Newsroom
- All journals
- Books

Keep up to date

Register to receive personalised research and resources by email

 Sign me up



Copyright © 2024 John Wiley & Sons, Inc. All rights reserved. John Wiley & Francis Group
Wiley is a registered trademark of John Wiley & Sons, Inc. All other trademarks are the property of their respective owners.

Accessibility

Registered
5 Howick Place

